TY - JOUR
T1 - A novel open-access artificial-intelligence-driven platform for CNS drug discovery utilizing adult zebrafish
AU - Lukovikov, Danil A.
AU - Kolesnikova, Tatiana O.
AU - Ikrin, Aleksey N.
AU - Prokhorenko, Nikita O.
AU - Shevlyakov, Anton D.
AU - Korotaev, Andrei A.
AU - Yang, Longen
AU - Bley, Vea
AU - de Abreu, Murilo S.
AU - Kalueff, Allan V.
N1 - Publisher Copyright:
© 2024
PY - 2024/11
Y1 - 2024/11
N2 - Background: Although zebrafish are increasingly utilized in biomedicine for CNS disease modelling and drug discovery, this generates big data necessitating objective, precise and reproducible analyses. The artificial intelligence (AI) applications have empowered automated image recognition and video-tracking to ensure more efficient behavioral testing. New method: Capitalizing on several AI tools that most recently became available, here we present a novel open-access AI-driven platform to analyze tracks of adult zebrafish collected from in vivo neuropharmacological experiments. For this, we trained the AI system to distinguish zebrafish behavioral patterns following systemic treatment with several well-studied psychoactive drugs - nicotine, caffeine and ethanol. Results: Experiment 1 showed the ability of the AI system to distinguish nicotine and caffeine with 75 % and ethanol with 88 % probability and high (81 %) accuracy following a post-training exposure to these drugs. Experiment 2 further validated our system with additional, previously unexposed compounds (cholinergic arecoline and varenicline, and serotonergic fluoxetine), used as positive and negative controls, respectively. Comparison with existing methods: The present study introduces a novel open-access AI-driven approach to analyze locomotor activity of adult zebrafish. Conclusions: Taken together, these findings support the value of custom-made AI tools for unlocking full potential of zebrafish CNS drug research by monitoring, processing and interpreting the results of in vivo experiments.
AB - Background: Although zebrafish are increasingly utilized in biomedicine for CNS disease modelling and drug discovery, this generates big data necessitating objective, precise and reproducible analyses. The artificial intelligence (AI) applications have empowered automated image recognition and video-tracking to ensure more efficient behavioral testing. New method: Capitalizing on several AI tools that most recently became available, here we present a novel open-access AI-driven platform to analyze tracks of adult zebrafish collected from in vivo neuropharmacological experiments. For this, we trained the AI system to distinguish zebrafish behavioral patterns following systemic treatment with several well-studied psychoactive drugs - nicotine, caffeine and ethanol. Results: Experiment 1 showed the ability of the AI system to distinguish nicotine and caffeine with 75 % and ethanol with 88 % probability and high (81 %) accuracy following a post-training exposure to these drugs. Experiment 2 further validated our system with additional, previously unexposed compounds (cholinergic arecoline and varenicline, and serotonergic fluoxetine), used as positive and negative controls, respectively. Comparison with existing methods: The present study introduces a novel open-access AI-driven approach to analyze locomotor activity of adult zebrafish. Conclusions: Taken together, these findings support the value of custom-made AI tools for unlocking full potential of zebrafish CNS drug research by monitoring, processing and interpreting the results of in vivo experiments.
KW - Deep learning
KW - Drug screening
KW - Foundation models
KW - Neural networks
KW - Object tracking
KW - Segmentation
KW - Zebrafish
UR - http://www.scopus.com/inward/record.url?scp=85202188991&partnerID=8YFLogxK
U2 - 10.1016/j.jneumeth.2024.110256
DO - 10.1016/j.jneumeth.2024.110256
M3 - Article
C2 - 39182516
AN - SCOPUS:85202188991
SN - 0165-0270
VL - 411
JO - Journal of Neuroscience Methods
JF - Journal of Neuroscience Methods
M1 - 110256
ER -